Article Abstract

Adipose tissue: enabler of prostate cancer aggressive behavior

Authors: Cameron A. Wade, Natasha Kyprianou

Abstract

Prostate cancer is an important contributor to cancer morbidity and mortality worldwide. In 2018, there was an estimated 164,690 new cases of prostate cancer and 29,430 deaths due to prostate cancer among American patients, making it the most common cause of cancer diagnosis in males (1). Prostate cancer is the second most common cause of cancer death among males, following respiratory tract malignancies (1). The historic discovery of androgen deprivation therapy (ADT) efficacy against prostate cancer by Huggins et al. in 1941 set the first line therapy for treatment that persists to this day (2,3). Since then, advances in therapy have improved the 5-year survival rate of non-metastatic prostate cancer to 98.9% but patients with metastatic disease upon diagnosis experienced only a modest 28.2% 5-year survival (4).